Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases

• US 20050250726A1
• Filed: 05/12/2005
• Published: 11/10/2005
• Est. Priority Date: 03/29/2001
• Status: Abandoned Application

• Current Assignee: University of Iowa Research Foundation
• Original Assignee: University of Iowa Research Foundation
• Inventors: Berg, Daniel J., Krieg, Arthur M.
• Application Number:
  US11/127,654
• Publication Number:
  US 20050250726A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/7125 Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides methods and compositions for using immunostimulatory nucleic acids to treat non-allergic inflammatory diseases. Non-allergic inflammatory diseases that may be treated according to the methods and products of the invention include psoriasis and inflammatory bowel disease. The invention further provides methods for augmenting a Th1 response to immunostimulatory nucleic acid involving inhibition of prostaglandin-mediated counter-regulatory response.

Claims

1-96. -96. (canceled)

97. A method of augmenting Th1-like immune activation in a subject, comprising:

administering to a subject in need of Th1-like immune activation an effective amount of an immunostimulatory nucleic acid to induce Th1-like immune activation; and

administering to the subject an effective amount of a cyclooxygenase inhibitor to inhibit prostaglandin expression, wherein the subject is free of symptoms of asthma or allergy otherwise calling for treatment with immunostimulatory nucleic acid, and wherein Th1-like immune activation induced by administering the immunostimulatory nucleic acid and the cyclooxygenase inhibitor is greater than Th1-like immune activation induced by administering the immunostimulatory nucleic acid alone.

98. The method of claim 97, wherein the prostaglandin is PGE₂.

99. The method of claim 97, wherein the cyclooxygenase inhibitor is a nonsteroidal anti-inflammatory drug (NSAID).

100. The method of claim 97, wherein the cyclooxygenase inhibitor is a selective inhibitor of COX-2 catalytic activity.